GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medartis Holding AG (XSWX:MED) » Definitions » Debt-to-EBITDA

Medartis Holding AG (XSWX:MED) Debt-to-EBITDA : 1.11 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Medartis Holding AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medartis Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF6.3 Mil. Medartis Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF20.6 Mil. Medartis Holding AG's annualized EBITDA for the quarter that ended in Dec. 2023 was CHF24.3 Mil. Medartis Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medartis Holding AG's Debt-to-EBITDA or its related term are showing as below:

XSWX:MED' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.3   Med: 2.03   Max: 5.28
Current: 1.06

During the past 10 years, the highest Debt-to-EBITDA Ratio of Medartis Holding AG was 5.28. The lowest was 0.30. And the median was 2.03.

XSWX:MED's Debt-to-EBITDA is ranked better than
53.15% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.24 vs XSWX:MED: 1.06

Medartis Holding AG Debt-to-EBITDA Historical Data

The historical data trend for Medartis Holding AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medartis Holding AG Debt-to-EBITDA Chart

Medartis Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 2.03 0.95 2.35 1.06

Medartis Holding AG Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 2.27 14.38 1.03 1.11

Competitive Comparison of Medartis Holding AG's Debt-to-EBITDA

For the Medical Devices subindustry, Medartis Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medartis Holding AG's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medartis Holding AG's Debt-to-EBITDA falls into.



Medartis Holding AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medartis Holding AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.297 + 20.627) / 25.383
=1.06

Medartis Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.297 + 20.627) / 24.284
=1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Medartis Holding AG  (XSWX:MED) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medartis Holding AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medartis Holding AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medartis Holding AG (XSWX:MED) Business Description

Traded in Other Exchanges
Address
Hochbergerstrasse 60E, Basel, CHE, 4057
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products and MODUS products. APTUS includes products for Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for Cranium, Midface, and mandible. Geographically, it derives majority of the revenue from EMEA and also has a presence in APAC; LATAM and North America.